CRISPR/Cas9-mediated gene disruption has been employed to generate a polyclonal knockout cell population targeting the LTBR gene in the Raji B lymphocyte line. The LTBR Knockout Raji Polyclonal Cells represent a heterogeneous collection of edited cells, each carrying loss-of-function modifications within the LTBR locus, thereby enabling population-level studies of lymphotoxin beta receptor (LTBR) function. This polyclonal format avoids single-clone selection, preserving broader genetic diversity and minimizing clonal artifacts, which is advantageous for investigations into signaling pathways and drug responses. The cells are suitable for a range of in vitro assays examining LTBR-dependent molecular events in a lymphoma background, providing a robust tool for dissecting receptor-mediated signaling mechanisms.
The parental Raji cell line is an Epstein-Barr virus (EBV)-positive Burkitt’s lymphoma-derived B lymphocyte model widely used to study immune signaling, lymphomagenesis, and host-virus interactions. This cell line exhibits constitutive activation of multiple signaling pathways, including the non-canonical NF-??B axis, partially driven by viral latent gene products. As a model B lymphocyte, Raji cells recapitulate aspects of B cell biology and lymphoma pathology, making them a relevant host for investigating LTBR contributions to malignant phenotypes and immune responses. The EBV-positive background also offers a unique context for exploring how viral factors intersect with host receptor signaling.
LTBR functions as a receptor for the trimeric tumor necrosis factor superfamily ligands LTA, LTB, and TNFSF14 (LIGHT). Upon engagement, LTBR recruits the adaptor proteins TRAF2 and TRAF3, which regulate downstream kinase cascades. A critical output is activation of the non-canonical NF-??B pathway: TRAF-mediated turnover of TRAF3 stabilizes MAP3K14 (NIK), which phosphorylates CHUK (IKK??), leading to NFKB2 p100 processing to p52 and nuclear translocation of the p52/RELB heterodimer. This signaling module transcriptionally upregulates targets such as CXCL13, BAFF (TNFSF13B), VCAM-1, and ICAM-1, which orchestrate chemokine production and cell adhesion. LTBR also interfaces with canonical NF-??B via RELA, as well as MAPK/ERK and apoptosis pathways through interactions with TRAF5 and IKBKG (NEMO).
In the Raji lymphoma context, LTBR knockout provides a defined loss-of-function model to study the receptor’s role in EBV-driven B cell lymphomagenesis and immune dysregulation. The model is particularly informative for dissecting non-canonical NF-??B signaling dependency, as LTBR cooperates with other stimuli to promote survival and proliferation. Research areas such as autoimmune lymphoproliferative syndrome, Sj?gren??s syndrome, and inflammatory bowel disease may benefit from using these cells to explore LTBR contributions to lymphoid tissue architecture and inflammation. The polyclonal nature allows analysis of heterogeneous cellular responses, mimicking tumor diversity.
Typical applications include Western blotting for pathway components such as phospho-IKK??, p52, and RELB; RT-qPCR analysis of CXCL13 and BAFF mRNA; NF-??B luciferase reporter assays; flow cytometric quantification of surface VCAM-1 and ICAM-1; and cell viability or apoptosis assays using Annexin V staining. The cells are also suited for drug sensitivity screening with NF-??B pathway inhibitors, enabling evaluation of therapeutic targets in lymphoma. Researchers can interrogate LTBR-dependent gene expression and functional cross-talk with the tumor microenvironment. For additional technical specifications or ordering information, please contact Ascent Research.
